Indication: Relapsed/Refractory Multiple Myeloma
Title: BOSTON: Bortezomib, selinexor, and Dexamethasone in Patients with Multiple Myeloma
Drug: selinexor

BOSTON is a Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study that will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade®) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with relapsed / refractory multiple myeloma who have received 1 to 3 prior anti-multiple myeloma (MM) regimens.

Velcade® plus low-dose dexamethasone is a standard therapy for previously treated multiple myeloma that is given by injection two times a week. Unlike other drugs used to treat multiple myeloma, selinexor is taken orally.

Patients enrolled in the BOSTON study will receive either Velcade® plus low-dose dexamethasone (standard therapy given on the recommended schedule) or selinexor plus standard therapy taken one time per week.

Please visit for more information about this study

This trial is for selinexor.


XPOVIO (selinexor) is approved in the U.S. in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Early StageMid StageLate StageCommercial